TELUS Corporation announced that it has hired TD Securities Inc. and Jefferies Securities, Inc. as financial advisors to evaluate a monetisation strategy for its TELUS Health division. The engagement will explore joint‑venture, equity‑investment, or sale options that could unlock value from a business that serves more than 160 million lives in over 200 countries and territories.
TELUS Health delivered strong year‑to‑date results for the first nine months of 2025, with operating revenue of $1.5 billion, EBITDA of $258 million and cash flow of $99 million. Those figures represent an 18 % increase in operating revenue and a 24 % rise in adjusted EBITDA compared with the same period in 2024, underscoring the division’s rapid growth and expanding global footprint.
The monetisation review is part of TELUS’s broader deleveraging plan, which aims to reduce the company’s net debt‑to‑EBITDA ratio from 3.4× in 2025 to 3.0× by the end of 2027. A successful transaction would generate a substantial cash infusion that could accelerate dividend growth and fund further investment in AI‑driven infrastructure, reinforcing TELUS’s competitive moat in both telecommunications and digital health.
CEO Darren Entwistle said the advisory engagement “demonstrates progress toward executing on the commitments we have made to the investment community.” He added that TELUS Health is a “world‑class digital asset” and that the monetisation strategy is focused on welcoming a strategic partner that can add complementary skills, customer reach and economic capacity to drive growth and scale.
The engagement signals that TELUS is positioning its core telecom business to remain focused while leveraging the high‑growth, high‑margin TELUS Health platform. If a sale or equity investment materialises, the company would free up capital that could be redeployed to core network upgrades or to deepen its AI capabilities, thereby sustaining long‑term shareholder value.
Industry analysts note that the digital health market is expanding rapidly, driven by virtual care, remote monitoring and data‑driven solutions. TELUS Health’s AI‑focused product set aligns with these tailwinds, making it an attractive partner for investors seeking exposure to the growing intersection of technology and health services.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.